Real-World Data
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. Explore our real-world data analyses to support your strategic decisions.
Featured Content
The Growing Presence of Pharmaceutical-Backed Corporate Venture Capital in Digital Health
As technology comes to the forefront in healthcare innovation, the venture capital arms of many pharmaceutical companies are solidifying their presence as key investors.
Comparing the Effectiveness of New Versus Established Multiple Sclerosis Therapies in the Managed Medicaid Population
Avalere experts recently presented their research, “Comparison of Healthcare Utilization Among Managed Medicaid Individuals Diagnosed with Multiple Sclerosis Treated with Emergent vs. Established Disease-Modifying Therapy in the US.”
Avalere Research and Expertise to be Featured at AMCP and ISPOR Conferences
In the coming months, Avalere experts will be presenting new data and research at major conferences, featuring insights derived from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®).
Opportunities for Real-World Data Will Grow as Big Tech Embraces Healthcare Partnerships
Partnerships between traditional healthcare players and big technology companies seek to improve care delivery and patient outcomes in innovative ways.
The Data Behind Social Determinants of Health Research
New Avalere study entitled “Using Aggregate Data to Proxy Individual-Level Socioeconomic Characteristics in Research on Medication Adherence: 9-Digit ZIP Code vs. Census Block Group” selected for the AMCP Foundation Best Poster Award at AMCP Nexus 2018.
Mental Illness Research Wins Award
Findings from a new Avalere study, titled “Prevalence and Likelihood of Hospital Admission and Readmission in Patients with Serious Mental Illness,” were presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific conference on Sunday, September 9, 2018.
Podcast: E3 – Real-World Evidence: Is It a Game Changer for the FDA?
Tune in to the final podcast in our series as we discuss 3 steps companies should complete now to take advantage of the FDA’s priority to advance the adoption of RWE to support agency decision-making.
HTA Oncology Recommendations Have Grown More Restrictive Over Time
Of the 329 oncology HTAs analyzed from the period 2013–2017, 29% resulted in positive recommendations without restrictions.
Podcast: E2 – Real-World Evidence: Is It a Game Changer for the FDA?
Tune in to episode 2 of our discussion covering why the FDA is so interested in real-world evidence and how they are approaching it.
Podcast: E1 – Real-World Evidence: Is It a Game Changer for the FDA?
Tune in to our new real-world evidence podcast series, where Avalere experts explore real-world evidence as a disruptive force in healthcare. In Episode 1, we focus on why RWE is such a hot topic.
Avalere Expands Actuarial and Data Analytics Expertise with Hire of Kenny Kan
Kenny Kan has joined the Avalere team leading the firm's actuarial analytics. Prior to joining Avalere, Kan served as the Chief Actuary at Humana and CareFirst.
Gillian Woollett’s Research Published in BioDrugs
Gillian Wollett, Senior Vice President of Avalere’s FDA & Regulatory Policy team, recently published “A ‘Global Reference’ Comparator for Biosimilar Development” in BioDrugs.
Webinar: Data-Driven Insights: The Future of Performance Improvement
Avalere and Inovalon experts discuss the strategic advantages of leveraging our proprietary assets.
Avalere Expands Analytic Offerings with Complete Suite of Medicare Claims Data
Today, Avalere announced that it has massively expanded its data and analytic capabilities through certification under the Centers for Medicare & Medicaid Services (CMS) Qualified Entity (QE) program.
Avalere to Participate in National Academies of Medicine Panel
On Tuesday, June 13, Christie Teigland, PhD, will participate in a panel discussion entitled “Measuring and Reporting Social Risk Factors” as part of a dissemination meeting on the report series “Accounting for Social Risk Factors in Medicare Payment,” sponsored by the National Academies of Medicine.
Webinar: Outcomes-Based Contracting: Master the Challenges
Avalere experts examine the challenges and successful approaches to outcomes-based contracts.
Health Plans Are Actively Exploring Outcomes-Based Contracts
Avalere experts say use of outcomes-based contracts could further goals to improve patient outcomes and manage drug costs
Avalere Panel Highlights the Importance of Analytics in Value-Based Care
At the Asembia Specialty Pharmacy Summit 2017, an Avalere-led panel identified three focus areas for specialty pharmacies looking to achieve market leadership in an increasingly value-based care environment.
Payer Insights on the Use of Patient Data
Avalere recently partnered with the National Pharmaceutical Council to examine payers' perspectives regarding the use of patient data and how it can be used to shape care delivery, improve system efficiencies, and achieve better health outcomes.
Avalere to Support Boehringer Ingelheim in Outcomes-Based Contracting
Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.